Douglas Cole - Editas Medicine Independent Director
| EDIT Stock | USD 5.46 0.14 2.50% |
Director
Dr. Douglas G. Cole M.D., is Independent Director of the company. He has served as a member of our board of directors since November 2013. Dr. Cole is a managing partner of venture firm Flagship Pioneering, where he has focused on life science investments since 2001. In the past five years, Dr. Cole has served on the boards of the following public biopharmaceutical companies Agios Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., Receptos, Inc., which was acquired by Celgene, Inc., and Tetraphase Pharmaceuticals, Inc. He also serves or has served on the boards of directors of several private biopharmaceutical and diagnostics companies, including Avedro, Inc., Denali Therapeutics, Inc., Ensemble Therapeutics Corporationrationration, Quanterix Corporationrationration, Selecta Biosciences, Inc., Seventh Sense Biosystems, Inc., and Torque Therapeutics, Inc since 2013.
| Age | 55 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.2087) % which means that it has lost $0.2087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4317) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Bitterman, Independent Director | ||
| Alexandra Glucksmann, COO | ||
| John Mendlein, Independent Director | ||
| Boris Nikolic, Independent Director | ||
| Vickesh Myer, CTO | ||
| Douglas Cole, Independent Director | ||
| Andrew Hirsch, Director | ||
| Gilmore MD, CEO President | ||
| Alexis Borisy, Independent Director | ||
| Gerald Cox, Chief Medical Officer | ||
| Gilmore ONeill, CEO President | ||
| James Mullen, Chairman of the Board | ||
| Mark Mullikin, Investor Relations Officer | ||
| Michelle Robertson, Principal CFO | ||
| Harry III, VP Operations | ||
| Eric Ek, Interim CFO, Principal Accounting Officer and Principal Financial Officer | ||
| Baisong MD, Senior Officer | ||
| Andrew Hack, CFO | ||
| Jessica Hopfield, Director | ||
| Linda Burkly, Executive Officer | ||
| Cynthia Collins, Director | ||
| Katrine Bosley, President CEO, Director | ||
| Doug Cole, Independent Director | ||
| Akshay Vaishnaw, Director | ||
| Charles Albright, Chief Scientific Officer | ||
| David Scadden, Director | ||
| Bruce Eaton, Exec Officer | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| David Liu, CoFounder Member | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Linea Aspesi, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.96) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 151.13 M | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 80.17 % | ||||
| Number Of Shares Shorted | 18.76 M | ||||
| Price To Earning | (7.02) X |
Editas Medicine Investors Sentiment
The influence of Editas Medicine's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Editas. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Editas Medicine's public news can be used to forecast risks associated with an investment in Editas. The trend in average sentiment can be used to explain how an investor holding Editas can time the market purely based on public headlines and social activities around Editas Medicine. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Editas Medicine's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Editas Medicine's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Editas Medicine's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Editas Medicine.
Editas Medicine Implied Volatility | 217.42 |
Editas Medicine's implied volatility exposes the market's sentiment of Editas Medicine stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Editas Medicine stock will not fluctuate a lot when Editas Medicine's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Editas Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Editas Medicine's short interest history, or implied volatility extrapolated from Editas Medicine options trading.
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
| 0.67 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Editas Stock
| 0.79 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.7 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.56 | ELYM | Eliem Therapeutics | PairCorr |
| 0.49 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.